GPRC5D-Targeted CAR T Cells for Myeloma

Overview of attention for article published in New England Journal of Medicine, September 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
Good Attention Score compared to outputs of the same age and source (67th percentile)

Mentioned by

news: 33 news outlets
blogs: 4 blogs
twitter: 133 X users
patent: 20 patents

facebook: 1 Facebook page
guideline: 2 clinical guideline sources
podcasts: 2 podcasts

Readers on

mendeley: 229 Mendeley

So far, Altmetric has seen 200 X posts from 133 X users, with an upper bound of 3,066,248 followers.

We know that GPRC5D is possibly expressed in the inferior olivary nucleus of the cerebellum. This has been previously reported in GPRC5D CART as a cerebellar syndrome https://t.co/8k5EZw1pZp

GPRC5D-Targeted CAR T Cells for Myeloma | New England Journal of Medicine https://t.co/KwmCqOWb97

@FrankJYF17 In this trial of GPRC5D CAR-T, the on-target off-tumor toxicities (skin, nail, etc) all eventually resolved. https://t.co/2KyRDF5rYw In clinical practice with GPRC5D bispecifics, the toxicity seems to persist, while you keep dosing the drugs…

https://t.co/SLBIVJwC9e

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 196 additional X posts.